Aventis Loses Second Lovenox Patent Reissuance Bid
French drug maker Aventis SA has vowed to continue fighting for a reissuance of a patent for its best-selling anti-blood clotting drug Lovenox, even though its application was rejected twice by...To view the full article, register now.
Already a subscriber? Click here to view full article